전이성 대장암에서 KRAS p.G12C 억제제의 효능에 대한 체계적 검토: 현재 과학의 현황

Boby 등(Thu,)이 이 문제를 연구했습니다.

www.synapsesocial.com/papers/69abc1765af8044f7a4ea11f — DOI: https://doi.org/10.1080/07357907.2026.2636581

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with <i>KRAS</i> G12C-mutant advanced solid tumors.· 2024 · 39 citations
2. Efficacy and safety of KRAS -G12C inhibitors in colorectal cancer: a systematic review of clinical trials· 2025 · 4 citations
3. 362P Phase Ia study to evaluate GDC-6036 monotherapy in patients with colorectal cancer (CRC) with KRAS G12C mutation· 2022 · 6 citations
4. Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.· 2023 · 11 citations
5. Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in <i>KRAS</i> G12C-mutant advanced colorectal cancer.· 2025 · 7 citations